Latest News and Press Releases

First ever demonstration that the spectrum of toxicities seen in CAR-T clinical trials can be effectively prevented in vivoEnhanced anti-tumor activity, improved overall survival, and improved...

Enhanced anti-tumor activity, improved overall survival, and an exponential increase in CAR-T cell proliferation was observed with GM-CSF neutralizationLenzilumab (an anti-GM-CSF antibody) used in...

Study Demonstrates a Significant Increase in Overall Survival in MiceRobust Anti-tumor Response with No Toxicity Using EphA3 Antibody Drug Conjugate (ADC) and Radioimmunotherapy (RIT) Approaches...

Lenzilumab (an anti-GM-CSF antibody) in combination with CAR-T cell therapy prevents cytokine release syndrome and neuroinflammation while improving durable control of leukemic diseaseExponential...

Lenzilumab (an anti-GM-CSF antibody) in combination with CAR-T cell therapy prevents cytokine release syndrome and neuro-inflammation while improving durable control of leukemic diseaseExponential...

Study Demonstrates that GM-CSF Neutralization with Lenzilumab in Combination with Chimeric Antigen Receptor T (CAR-T) Cell Therapy Prevents the Onset of Cytokine Release Syndrome, Significantly...

Study Demonstrates that GM-CSF Blockade in Combination with Chimeric Antigen Receptor T Cell Therapy (CAR-T) Prevents the Onset and Severity of Neurotoxicity and Cytokine Release Syndrome BURLINGAME,...

BURLINGAME, Calif., May 30, 2018 (GLOBE NEWSWIRE) -- Humanigen, Inc. (OTCQB:HGEN), a biopharmaceutical company developing cutting-edge T-cell optimization and oncology treatments, today announced...

Lenzilumab effectively neutralizes GM-CSF CAR-T cells maintained robust anti-tumor activity in combination with lenzilumab GM-CSF depletion by lenzilumab may increase CAR-T expansion BRISBANE,...

BRISBANE, Calif., April 30, 2018 (GLOBE NEWSWIRE) -- Humanigen, Inc. (OTCQB:HGEN), a biopharmaceutical company developing cutting-edge CAR-T optimization and oncology treatments, today announced...